A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab

Trial Identifier: D907HC00001
Sponsor: AstraZeneca
Start Date: March 2026
Primary Completion Date: August 2027
Study Completion Date: August 2027
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AU Fitzroy, AU, 3065
AU St Albans, AU, 3021
AU Woolloongabba, AU, 4102
GE Batumi, GE, 6010
GE Tbilisi, GE, 0114
GE Tbilisi, GE, 0112
KR Seongnam-si, KR, 13620
KR seoul, KR, 06351
KR Seoul, KR, 5505
KR Seoul, KR, 03722
PL Brzozow, PL, 36-200
PL Koszalin, PL, 75-581
PL Lublin, PL, 20-090
PL Olsztyn, PL, 10-357
PL Przemysl, PL, 37-700
TW Tainan City, TW, 73657
TW Taipei, TW, 112
TW Taipei City, TW, 110
TW Taoyuan, TW, 333